RXi Pharmaceuticals to Present at the 12th Annual BIO Investor Forum

     RXi Pharmaceuticals to Present at the 12th Annual BIO Investor Forum

PR Newswire

WESTBOROUGH, Mass., Sept. 17, 2013

WESTBOROUGH, Mass., Sept. 17, 2013 /PRNewswire/ --RXi Pharmaceuticals
Corporation (OTCQX: RXII), a biotechnology company focused on discovering,
developing and commercializing innovative therapies addressing major unmet
medical needs using RNA-targeted technologies, today announced that the
Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will
present at the 12th Annual BIO Investor Forum on Tuesday, October 8, 2013 at
2:00pm PDT. Dr. Cauwenbergh will discuss the development of RXI-109, a
self-delivering RNAi compound designed to reduce dermal scarring, as well as
business development opportunities with RXi's sd-rxRNA® technology platform.

(Logo: http://photos.prnewswire.com/prnh/20130917/NE80755LOGO)

A live webcast of the presentation will be available on the "Investors"
section of the Company's website, www.rxipharma.com. A replay of the
presentation will be available 90 days.

Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO
Investor Forum features leading private and emerging public companies. The
meeting will take place October 8-9 at the Palace Hotel in San Francisco,
California. To schedule a meeting with RXi Pharmaceuticals at this
conference, please submit your request to tmcgrillen@rxipharma.com.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTCQX: RXII) is a biotechnology company
focused on discovering, developing and commercializing innovative therapies
based on its proprietary, self-delivering RNAi platform. Therapeutics that use
RNA interference, or "RNAi," have great promise because of their ability to
down-regulate, the expression of a specific gene that may be over-expressed in
a disease condition. Building on the pioneering work of scientific founder and
Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board,
RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth
factor (CTGF) to reduce dermal scarring (fibrosis), entered into human
clinical trials in June 2012. For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about future expectations, planned and
future development of RXi Pharmaceuticals Corporation's products and
technologies. Forward-looking statements about expectations and development
plans of RXi's products involve significant risks, and uncertainties: risks
that RXi may not be able to successfully develop its candidates, or that
development of RNAi-based therapeutics may be delayed or not proceed as
planned, or that we may not develop any RNAi-based product; risks that the
development process for our product candidates may be delayed, risks related
to development and commercialization of products by our competitors, risks
related to our ability to control timing and terms of collaborations with
third parties, and the possibility that other companies or organizations may
assert patent rights preventing us from developing our products. Actual
results may differ from those contemplated by these forward-looking
statements. RXi does not undertake to update forward-looking statements to
reflect a change in its views, events or circumstances that occur after the
date of this release.


RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646

SOURCE RXi Pharmaceuticals Corporation

Website: http://www.rxipharma.com
Press spacebar to pause and continue. Press esc to stop.